Refractory pityriasis rubra pilaris treated with abrocitinib
https://doi.org/10.4081/dr.2025.10105
Accepted: 5 January 2025
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Pityriasis rubra pilaris is a rare idiopathic papulosquamous disorder that significantly impacts the quality of life and is often refractory to conventional therapies. This study presents a case of successful treatment with an abrocitinib JAK1 inhibitor after several conventional and biologic therapies failed.
Ross NA, Chung H-J, Li Q, et al. Epidemiologic, clinicopathologic, diagnostic, and management challenges of pityriasis rubra pilaris: a case series of 100 patients. JAMA Dermatol 2016;152:670–5. DOI: https://doi.org/10.1001/jamadermatol.2016.0091
Joshi TP, Duvic M. Pityriasis Rubra Pilaris: An Updated Review of Clinical Presentation, Etiopathogenesis, and Treatment Options. Am J clin Dermatol 2024;25:243-59. DOI: https://doi.org/10.1007/s40257-023-00836-x
Ji-Xu A, Lei DK, Worswick S, et al. Patient and disease characteristics associated with psychiatric symptoms and impaired quality of life in pityriasis rubra pilaris. Br J Dermatol 2022;187:1024–6. DOI: https://doi.org/10.1111/bjd.21792
Chandy RJ, Chokshi A, Tan I, Feldman SR. Biologics for Treatment of Pityriasis Rubra Pilaris: A Literature Review. J Cut Med Surg 2024;12034754241238735. DOI: https://doi.org/10.1177/12034754241238735
Strunck JL, Cutler B, Rajpal B, et al. Pityriasis rubra pilaris response to IL-17A inhibition is associated with IL-17C and CCL20 protein levels. J Invest Dermatol 2022;142:235-9. DOI: https://doi.org/10.1016/j.jid.2021.06.009
Abduljawad M, Alsharif TH, Gronfula AG, et al. The effectiveness of anti-interleukin-17A treatment for pityriasis rubra pilaris: A systematic review. Cureus 2023;15:6. DOI: https://doi.org/10.7759/cureus.41125
Feldmeyer L, Mylonas A, Demaria O, et al. Interleukin 23-helper T cell 17 axis as a treatment target for pityriasis rubra pilaris. JAMA Dermatol 2017;153:304–8. DOI: https://doi.org/10.1001/jamadermatol.2016.5384
Ying Y, Yu-Hua L, Xiao-Yan W, Su-Chun H. A case of pityriasis rubra pilaris treated with tofacitinib after failure with acitretin and ixekizumab. Australas J Dermatol 2023;64:445–7. DOI: https://doi.org/10.1111/ajd.14076
Saad M, Spurr A, Lipson J. Pityriasis rubra pilaris partially responsive to treatment with upadacitinib: a case report. SAGE Open Med Case Rep 2023;11:2050313X231160927. DOI: https://doi.org/10.1177/2050313X231160927
Song EJ, Al-Saedy MA, Bouché N. Refractory pityriasis rubra pilaris treated with upadacitinib. JAAD Case Rep 2023;35:112–4. DOI: https://doi.org/10.1016/j.jdcr.2023.03.004
Li Y, Chen Z, He M, et al. Successful treatment of erythrodermic pityriasis rubra pilaris with upadacitinib. J Eur Acad Dermatol Venereol 2023;38:e593-5. DOI: https://doi.org/10.1111/jdv.19762
Ying L, Xiaoyuan Z, Dawei H, et al. Efficacy and safety of oral abrocitinib monotherapy in pityriasis rubra pilaris. J Eur Acad Dermatol Venereol 2024; Mar 30.
Ytterberg SR, Bhatt DL, Mikuls TR, et al. Cardiovascular and cancer risk with tofacitinib in rheumatoid arthritis. N Engl J Med 2022;386:316–26. DOI: https://doi.org/10.1056/NEJMoa2109927
Samuel C, Cornman H, Kambala A, Kwatra SG. A review on the safety of using JAK inhibitors in dermatology: clinical and laboratory monitoring. Derm Ther 2022;13:729-49. DOI: https://doi.org/10.1007/s13555-023-00892-5
Copyright (c) 2025 the Author(s)
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
PAGEPress has chosen to apply the Creative Commons Attribution NonCommercial 4.0 International License (CC BY-NC 4.0) to all manuscripts to be published.
Downloads
Citations
